Cerveau, Prothena to use novel tau biomarker for research into neurodegenerative disease
Click Here to Manage Email Alerts
Cerveau Technologies Inc. announced a partnership with Othair Prothena Limited, which will allow Prothena to use Cerveau’s investigational imaging agent in positron emission tomography scans to assess neurofibrillary tangles in the brain.
According to a release from Cerveau, the collaboration centers around the company’s [F-18] MK-6240 biomarker, which will be employed in Prothena’s drug research and development for neurodegenerative diseases, particularly Alzheimer’s disease.
“Cerveau is focused on enabling acceleration of technologies that have the potential to advance the fight against debilitating neurodegenerative diseases,” Rick Hiatt, CEO of Cerveau Technologies, stated in the release. “We are excited to add Prothena to our growing network of pharmaceutical partners and global validated production sites. Our goal is to expand the availability of this novel investigational imaging agent to the broader scientific community.”